🏛️ Verified NIH Record • Updated 2025-06-11

MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect (NCT05816122)

🔵 Active, Not Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: Ad scientiam

🩺 Plain-English Summary (8th-Grade Level)

The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS). The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution. A secondary objective is to determine MSCopilot® Detect's ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients. Exploratory objectives include evaluating the relationship between MSCopilot® Detect composite and individual scores and other biomarkers such as MRI, soluble glial fibrillary acidic protein (sGFAP), and soluble neurofilament light chain (sNfL). Patients will be able to download the free MSCopilot® Detect app. They will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). Every 3 months, patients will complete validated questionnaires regarding MS symptoms and quality of life and participate in digital tests designed to monitor MS symptom progression. The study will include 336 MS patients and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France

Who can join: Review the eligibility criteria below.

Location: Jennifer Graves — San Diego, California

Age range: 30 Years to 65 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (34 Sites)

Showing the first 25 of 34 sites.

  • Jennifer Graves — San Diego, California
  • Joash Lazarus Sr. — Atlanta, Georgia
  • Daniel Wynn — Northbrook, Illinois
  • Craig E. Herrman — Indianapolis, Indiana
  • Jennifer Feng — New Orleans, Louisiana
  • Robert Naismith — St Louis, Missouri
  • Aaron Boster — Columbus, Ohio
  • Gabriel Pardo — Oklahoma City, Oklahoma
  • Vijayshree Yadav — Portland, Oregon
  • Leorah Freeman — Austin, Texas
  • Galina Vorobeychik — Burnaby,
  • Mark Freedman — Ottawa,
  • St. Michael's Hospital — Toronto,
  • Robert Carruthers — Vancouver,
  • University Hospital of Southern Denmark — Esbjerg,
  • Finn Sellebjerg — Glostrup Municipality,
  • Sivagini Prakash — Viborg,
  • Hôpital Roger Salengro — Lille,
  • Cécile Donzé — Lomme,
  • Adil Maarouf — Marseille,
  • Mikael Cohen — Nice,
  • Bertrand Bourre — Rouen,
  • Boris-Alexander Kallman — Bayreuth,
  • Universitätsklinikum Carl Gustav Carus — Dresden,
  • Rupert Knoblich — Erbach im Odenwald,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Sclerosis

Explore by condition: All Multiple Sclerosis clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗